Some tumours, notably fibrosarcomas induced in rodents with polycyclic hydrocarbon carcinogens, possess antigens termed tumour associated transplantation antigens (TATA) (See Woodruff, 1980 for review) which induce resistance to transplants of the tumour in hosts syngeneic with the one in which the tumour originated (the autochthonous host). It has also been shown that transplants of some tumours induce resistance in the autochthonous host itself, although as Klein & Oettgen (1969) have pointed out, "this does.not, in the strict sense, answer the question of whether, and to what extent, the primary host can mobilize a rejection response against its own tumour cells as they increase in number at their natural pace and at the site of origin."
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The TATA of chemically-induced murine fibrosarcomas are remarkably polymorphic. Moreover, as Prehn & Main (1957) first reported, there is often, though not invariably, no demonstrable cross reactivity between the TATA of different sarcomas induced with the same carcinogen, including sarcomas induced at different sites in the same mouse (Globerson & Feldman, 1964; Rosenau & Morton, 1966) . Differences in TATA specificity between tumour sublines established by Correspondence: M.F.A. Woodruff Received 8 August 1983; accepted 19 September 1983. transplantation of tissue from opposite poles of the same tumour have also been demonstrated (Prehn, 1970; Pimm et al., 1980) . We now report two instances in which a pair of clones from the same primary tumour, chosen at random except for the proviso that they bore different alloenzyme markers, though strongly antigenic, showed no evidence of cross reactivity. Moreover the clonal composition of tumours produced by inoculating a mixture of two clones from the same tumour was radically altered by prior immunization with one of them.
The tumours had been induced with methylcholanthrene (MC) in female backcross CBA mice (Pgk-la/PGK-lb, abbreviated to AB) heterozygous for two forms (A and B) of the enzyme phosphoglycerate kinase-1. In tissue culture the first tumour (numbered W319 or DlI) expressed both A and B alloenzymes in substantial amounts in all cultures for several culture generations, A being the larger component in some cultures and B in others. The second tumour (numbered W324 or S1O) expressed only the B alloenzyme in primary culture, but both A and B in substantial amounts in all subsequent cultures. Numerous clones expressing either A only or B only were isolated from both tumours and stored in liquid nitrogen; in addition, some clones expressing both A and B were isolated from SlO, and both components persisted on re-cloning and also on re-recloning after passage in vivo.
Materials and methods

Tumour and clones
The origin of the tumours and their alloenzyme phenotypes, the method of preparing tumour cell suspensions, and the techniques of tissue culture and cloning have been described previously (Woodruff et al., 1982a ).
An A clone and a B clone were chosen at random from each tumour. They were numbered as follows:
Clone 6 (C6) expressing A, and Clone 12 (C12) expressing B, from tumour Dl 1.
Clone 17 (Cl7) expressing A, clone 49 (C49) expressing B, and clone 2 reclone 11 (C2RC11) expressing A and B, from S10.
All clones were passaged once in irradiated (4.7 Gy) CBA mice, and then one or more times in untreated CBA mice, before being used in the experiments. This is a generalization of the method used previously (Woodruff et al., 1982b) to express the capacity of a tumour cell population to evoke transplant immunity against itself.
Mice
Alloenzyme assays
To assess the proportion of each clone in tumours which developed after challenge with a mixed population, PGK-1 alloenzyme assays were performed on samples derived from these tumours and also, as controls, from tumours which developed after single clone challenge. Since whole tumour suspensions contain a proportion of normal cells, assays were also performed on tissue cultures and subcultures derived from them. In a few cases whole tumour suspensions were also injected to mice of one or other phenotype.
The techniques were, with minor modifications, the same as those previously reported (Woodruff et al., 1982a Tables I and II. It will be seen that, as judged by the response of immunized mice to challenge with viable tumour (Table  III , lines 6 and 10), indicating that these clones have some antigens in common.
Discussion
It seems clear that, with both the tumours studied, a pair of clones chosen randomly, except for the proviso that they were of different alloenzyme (Woodruff et al., 1982a) , clones like C2 that express both alloenzyme phenotypes have arisen from hybrid cells, the simplest explanation is that C2 has developed from a hybrid formed by the fusion of a cell belonging to C17 with a cell expressing PGK-1 B but not belonging to C49. Further experiments are planned to test this hypothesis.
Autochthonous pleoclonal tumours are also exposed to selection pressures, and the extent to which a particular clone is favoured will depend not only on its intrinsic properties but also on extrinsic factors which affect the host reaction, including therapeutic procedures of various kinds.
It is widely accepted that the TATA of most chemically induced tumours are distinctive and stable characteristics of each individual tumour (Baldwin et al., 1979) . The claim of stability rests mainly on the observation that, as a rule, a primary tumour that is strongly, weakly or nonimmunogenic retains this property for many generations when serially transplanted in the strain of origin (Prehn, 1982) , but important exceptions to this rule have been reported. Globerson and Feldman (1964) , for example, found that highly immunogenic benzopyrene-induced sarcomas regularly lost their immunogenicity within three transplant generations, and Prehn (1982) himself observed that the immunogenicity of a tumour sometimes appeared to rise or fall in successive transplant generations "without any apparent reason." There is less evidence concerning the extent to which antigenic specificity remains constant. Globerson & Feldman (1964) reported that tumours that could no longer immunize animals were still susceptible to the immune response elicited by immunogenic grafts of earlier transplant generations, but in only two instances was the test graft more than one transplant generation removed-from the immunizing graft.
The discovery that methylcholanthrene-induced murine sarcomas are often pleoclonal (Reddy & Fialkow, 1979; Woodruff et al., 1982a) , and that their clonal composition may change markedly on transplantation or in tissue culture (Woodruff et al., 1982a) , coupled with our present findings, implies however that antigenic specificity may also be unstable, because changes in clonal composition may result in corresponding changes in the TATA expressed by the tumour. We see no compelling reason to postulate that the antigens expressed by individual clones may also change, but this possibility cannot be excluded on the evidence available.
Little is known about the factors which regulate the clonal composition of tumours but our results show that, with an immunogenic tumour, striking changes may be produced by manipulation of the host's immunological response. Our experiments illustrate elimination of a particular clone but the possibility of immunostimulation (Prehn, 1976 (Prehn, , 1982 must also be considered.
Although nearly 30 years have elapsed since the polymorphism of the TATA of chemically-induced tumour was discovered (Baldwin, 1955; Prehn & Main, 1957) , the molecular basis for their diversity is still unknown (Parmiani & Pierotti, 1983) . One suggestion, put forward by Lennox (1980) , is that the specificity of the TATA of chemically induced murine sarcomas is carried on envelope glycoprotein (gp7O) molecules of mouse leukaemia retroviruses (MuLV). There is good evidence that these tumours may express MuLV antigens which are detectable serologically, and it may well be true, as Lennox has claimed, that MuLV is sufficiently polymorphic to account for the great diversity of their TATA; but comparison of the amino acid composition of TATA isolated from an MCinduced fibrosarcoma and gp7O from the Rauscher strain of MuLV (Du Bois et al., 1982) does not support Lennox's hypothesis.
It might be rewarding to use the methods of Du Bois et al. (1982) to purify TATA from tumour clones. It would also be of interest to raise monoclonal antibodies to tumour clones by the technique, already used with whole tumours (Simrell & Klein, 1979; Lennox et al., 1981) , in which myeloma cells are fused with spleen cells from tumour bearing animals, and to study reactions between antibodies raised with one clone and the cells of other clones from the same tumour.
